NF-κB in innate neuroprotection and age-related neurodegenerative diseases

Frontiers in Neurology

Volumn 6, Issue MAY, 2015, Pages

  Lanzillotta, Annamaria ^a   Porrini, Vanessa ^a,b   Bellucci, Arianna ^a   Benarese, Marina ^a   Branca, Caterina ^a   Parrella, Edoardo ^a   Spano, Pier Franco ^a,b   Pizzi, Marina ^a,b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

BDNF; C Rel deficient mice; Epigenetic drugs; NF B; RelA (K310)

Indexed keywords

ALPHA SYNUCLEIN; BENSERAZIDE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE TRANSPORTER; ENTINOSTAT; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEVODOPA; PROTEIN P50; RESVERATROL; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA;

AGING; ARTICLE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; DRUG POTENTIATION; HISTONE MODIFICATION; HUMAN; ISCHEMIC PRECONDITIONING; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PROTEIN ACETYLATION; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA;

EID: 84930664415     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00098     Document Type: Article

References (87)

1. Crampton SJ, O'Keeffe GW. NF-κB: emerging roles in hippocampal development and function. Int J Biochem Cell Biol (2013) 45(8):1821-4. doi: 10.1016/j.biocel.2013.05.037.
2. Pizzi M, Spano P. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur J Pharmacol (2006) 545(1):22-8. doi:10.1016/j.ejphar.2006.06.027.
3. Camandola S, Mattson MP. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets (2007) 11(2):123-32. doi:10.1517/14728222.11.2.123.
4. Inta I, Paxian S, Maegele I, Zhang W, Pizzi M, Spano P, et al. Bim and Noxa are candidates to mediate the deleterious effect of the NF-kappa B subunit RelA in cerebral ischemia. J Neurosci (2006) 26(50):12896-903. doi:10.1523/JNEUROSCI.3670-06.2006.
5. Pizzi M, Boroni F, Bianchetti A, Moraitis C, Sarnico I, Benarese M, et al. Expression of functional NR1/NR2B-type NMDA receptors in neuronally differentiated SK-N-SH human cell line. Eur J Neurosci (2002) 16(12):2342-50. doi:10.1046/j.1460-9568.2002.02403.x.
6. Pizzi M, Sarnico I, Boroni F, Benetti A, Benarese M, Spano PF. Inhibition of IkappaBalpha phosphorylation prevents glutamate-induced NF-kappaB activation and neuronal cell death. Acta Neurochir Suppl (2005) 93:59-63. doi:10.1007/3-211-27577-0_8.
7. Pizzi M, Sarnico I, Boroni F, Benarese M, Steimberg N, Mazzoleni G, et al. NF-kappaB factor c-Rel mediates neuroprotection elicited by mGlu5 receptor agonists against amyloid beta-peptide toxicity. Cell Death Differ (2005) 12(7):761-72. doi:10.1038/sj.cdd.4401598.
8. Lanzillotta A, Sarnico I, Ingrassia R, Boroni F, Branca C, Benarese M, et al. The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury. Cell Death Dis (2010) 1:e96. doi:10.1038/cddis.2010.76.
9. Sarnico I, Lanzillotta A, Boroni F, Benarese M, Alghisi M, Schwaninger M, et al. NF-kappaB p50/RelA and c-Rel-containing dimers: opposite regulators of neuron vulnerability to ischaemia. J Neurochem (2009) 108(2):475-85. doi:10.1111/j.1471-4159.2008.05783.x.
10. Baiguera C, Alghisi M, Pinna A, Bellucci A, De Luca MA, Frau L, et al. Late-onset parkinsonism in NF?B/c-Rel-deficient mice. Brain (2012) 135(Pt 9):2750-65. doi:10.1093/brain/aws193.
11. Adler AS, Sinha S, Kawahara TL, Zhang JY, Segal E, Chang HY. Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev (2007) 21(24):3244-57. doi:10.1101/gad.1588507.
12. Zhang G, Li J, Purkayastha S, Tang Y, Zhang H, Yin Y, et al. Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH. Nature (2013) 497(7448):211-6. doi:10.1038/nature12143.
13. Tilstra JS, Robinson AR, Wang J, Gregg SQ, Clauson CL, Reay DP, et al. NF-κB inhibition delays DNA damage-induced senescence and aging in mice. J Clin Invest (2012) 122(7):2601-12. doi:10.1172/JCI45785.
14. Koo JW, Russo SJ, Ferguson D, Nestler EJ, Duman RS. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A (2010) 107(6):2669-74. doi:10.1073/pnas.0910658107.
15. Rolls A, Shechter R, London A, Ziv Y, Ronen A, Levy R, et al. Toll-like receptors modulate adult hippocampal neurogenesis. Nat Cell Biol (2007) 9(9):1081-8. doi:10.1038/ncb1629.
16. Levenson JM, Choi S, Lee SY, Cao YA, Ahn HJ, Worley KC, et al. A bioinformatics analysis of memory consolidation reveals involvement of the transcription factor c-rel. J Neurosci (2004) 24(16):3933-43. doi:10.1523/JNEUROSCI.5646-03.2004.
17. Ahn HJ, Hernandez CM, Levenson JM, Lubin FD, Liou HC, Sweatt JD. c-Rel, an NF-kappaB family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formation. Learn Mem (2008) 15(7):539-49. doi:10.1101/lm.866408.
18. O'Riordan KJ, Huang IC, Pizzi M, Spano P, Boroni F, Egli R, et al. Regulation of nuclear factor kappaB in the hippocampus by group I metabotropic glutamate receptors. J Neurosci (2006) 26(18):4870-9. doi:10.1523/JNEUROSCI.4527-05.2006.
19. Bethea JR, Castro M, Keane RW, Lee TT, Dietrich WD, Yezierski RP. Traumatic spinal cord injury induces nuclear factor-kappaB activation. J Neurosci (1998) 18(9):3251-60.
20. Schneider A, Martin-Villalba A, Weih F, Vogel J, Wirth T, Schwaninger M. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat Med (1999) 5(5):554-9. doi:10.1038/6458.
21. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 104(47):18754-9. doi:10.1073/pnas.0704908104.
22. Hunot S, Brugg B, Ricard D, Michel PP, Muriel MP, Ruberg M, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci U S A (1997) 94(14):7531-6. doi:10.1073/pnas.94.14.7531.
23. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A (1997) 94(6):2642-7. doi:10.1073/pnas.94.6.2642.
24. Valerio A, Boroni F, Benarese M, Sarnico I, Ghisi V, Bresciani LG, et al. NF-kappaB pathway: a target for preventing beta-amyloid (Abeta)-induced neuronal damage and Abeta42 production. Eur J Neurosci (2006) 23(7):1711-20. doi:10.1111/j.1460-9568.2006.04722.x.
25. Sarnico I, Boroni F, Benarese M, Sigala S, Lanzillotta A, Battistin L, et al. Activation of NF-kappaB p65/c-Rel dimer is associated with neuroprotection elicited by mGlu5 receptor agonists against MPP(+) toxicity in SK-N-SH cells. J Neural Transm (2008) 115(5):669-76. doi:10.1007/s00702-007-0007-2.
26. Yang HJ, Wang L, Xia YY, Chang PN, Feng ZW. NF-kappaB mediates MPP+-induced apoptotic cell death in neuroblastoma cells SH-EP1 through JNK and c-Jun/AP-1. Neurochem Int (2010) 56(1):128-34. doi:10.1016/j.neuint.2009.09.010.
27. Kögel D, Peters M, König HG, Hashemi SM, Bui NT, Arolt V, et al. S100B potently activates p65/c-Rel transcriptional complexes in hippocampal neurons: clinical implications for the role of S100B in excitotoxic brain injury. Neuroscience (2004) 127(4):913-20. doi:10.1016/j.neuroscience.2004.06.013.
28. Valerio A, Dossena M, Bertolotti P, Boroni F, Sarnico I, Faraco G, et al. Leptin is induced in the ischemic cerebral cortex and exerts neuroprotection through NF-kappaB/c-Rel-dependent transcription. Stroke (2009) 40(2):610-7. doi:10.1161/STROKEAHA.108.528588.
29. Bernard D, Quatannens B, Begue A, Vandenbunder B, Abbadie C. Antiproliferative and antiapoptotic effects of crel may occur within the same cells via the up-regulation of manganese superoxide dismutase. Cancer Res (2001) 61(6):2656-64.
30. Chen C, Edelstein LC, Gélinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol (2000) 20(8):2687-95. doi:10.1128/MCB.20.8.2687-2695.2000.
31. Ho JW, Ho PW, Liu HF, So DH, Chan KH, Tse ZH, et al. UCP4 is a target effector of the NF-κB c-Rel prosurvival pathway against oxidative stress. Free Radic Biol Med (2012) 53(2):383-94. doi:10.1016/j.freeradbiomed.2012.05.002.
32. Echtay KS. Mitochondrial uncoupling proteins-what is their physiological role? Free Radic Biol Med (2007) 43(10):1351-71. doi:10.1016/j.freeradbiomed.2007.08.011.
33. Calandria JM, Asatryan A, Balaszczuk V, Knott EJ, Jun BK, Mukherjee PK, et al. NPD1-mediated stereoselective regulation of BIRC3 expression through cREL is decisive for neural cell survival. Cell Death Differ (2015). doi:10.1038/cdd.2014.233.
34. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell (2008) 30(6):689-700. doi:10.1016/j.molcel.2008.05.014.
35. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A (2008) 105(33):11778-83. doi:10.1073/pnas.0711122105.
36. Crack PJ, Taylor JM, Ali U, Mansell A, Hertzog PJ. Potential contribution of NF-kappaB in neuronal cell death in the glutathione peroxidase-1 knockout mouse in response to ischemia-reperfusion injury. Stroke (2006) 37(6):1533-8. doi:10.1161/01.STR.0000221708.17159.64.
37. Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, et al. IKK mediates ischemia-induced neuronal death. Nat Med (2005) 11(12):1322-9. doi:10.1038/nm1323.
38. Nurmi A, Lindsberg PJ, Koistinaho M, Zhang W, Juettler E, Karjalainen-Lindsberg ML, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke (2004) 35(4):987-91. doi:10.1161/01.STR.0000120732.45951.26.
39. Pizzi M, Sarnico I, Lanzillotta A, Battistin L, Spano P. Post-ischemic brain damage: NF-kappaB dimer heterogeneity as a molecular determinant of neuron vulnerability. FEBS J (2009) 276(1):27-35. doi:10.1111/j.1742-4658.2008.06767.x.
40. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci (2002) 22(13):5423-31.
41. Ingrassia R, Lanzillotta A, Sarnico I, Benarese M, Blasi F, Borgese L, et al. 1B/(-)IRE DMT1 expression during brain ischemia contributes to cell death mediated by NF-κB/RelA acetylation at Lys310. PLoS One (2012) 7(5):e38019. doi:10.1371/journal.pone.0038019.
42. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Activation of the nuclear factor-kappaB is a key event in brain tolerance. J Neurosci (2001) 21(13):4668-77.
43. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol (2004) 5(5):392-401. doi:10.1038/nrm1368.
44. Lanzillotta A, Pignataro G, Branca C, Cuomo O, Sarnico I, Benarese M, et al. Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window. Neurobiol Dis (2013) 49:177-89. doi:10.1016/j.nbd.2012.08.018.
45. Sweatt JD. Experience-dependent epigenetic modifications in the central nervous system. Biol Psychiatry (2009) 65(3):191-7. doi:10.1016/j.biopsych.2008.09.002.
46. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet (2009) 10(1):32-42. doi:10.1038/nrg2485.
47. Kiernan R, Brès V, Ng RW, Coudart MP, El Messaoudi S, Sardet C, et al. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem (2003) 278(4):2758-66. doi:10.1074/jbc.M209572200.
48. Ashburner BP, Westerheide SD, Baldwin AS. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol (2001) 21(20):7065-77. doi:10.1128/MCB.21.20.7065-7077.2001.
49. Buck SW, Gallo CM, Smith JS. Diversity in the Sir2 family of protein deacetylases. J Leukoc Biol (2004) 75(6):939-50. doi:10.1189/jlb.0903424.
50. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J (2004) 23(12):2369-80. doi:10.1038/sj.emboj.7600244.
51. Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, et al. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol Pharmacol (2006) 70(6):1876-84. doi:10.1124/mol.106.027912.
52. Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci U S A (2006) 103(5):1587-92. doi:10.1073/pnas.0510341103.
53. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov (2006) 5(6):493-506. doi:10.1038/nrd2060.
54. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 3:5. doi:10.1186/1756-8722-3-5.
55. Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem (2012) 113(3):752-9. doi:10.1002/jcb.23431.
56. Agrawal M, Kumar V, Kashyap MP, Khanna VK, Randhawa GS, Pant AB. Ischemic insult induced apoptotic changes in PC12 cells: protection by trans resveratrol. Eur J Pharmacol (2011) 666(1-3):5-11. doi:10.1016/j.ejphar.2011.05.015.
57. Li H, Yan Z, Zhu J, Yang J, He J. Neuroprotective effects of resveratrol on ischemic injury mediated by improving brain energy metabolism and alleviating oxidative stress in rats. Neuropharmacology (2011) 60(2-3):252-8. doi:10.1016/j.neuropharm.2010.09.005.
58. Morris KC, Lin HW, Thompson JW, Perez-Pinzon MA. Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning. J Cereb Blood Flow Metab (2011) 31(4):1003-19. doi:10.1038/jcbfm.2010.229.
59. Ren J, Fan C, Chen N, Huang J, Yang Q. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem Res (2011) 36(12):2352-62. doi:10.1007/s11064-011-0561-8.
60. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature (2003) 425(6954):191-6. doi:10.1038/nature01960.
61. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, Lan F, et al. AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab (2010) 298(4):E751-60. doi:10.1152/ajpendo.00745.2009.
62. Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE, Bartlett PF. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J Neurochem (1999) 72(4):1707-16. doi:10.1046/j.1471-4159.1999.721707.x.
63. Raval AP, Dave KR, Pérez-Pinzón MA. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab (2006) 26(9):1141-7. doi:10.1038/sj.jcbfm.9600262.
64. Lanzillotta A, Porrini V, Bellucci A, Benarese M, Branca C, Parrella E, et al. NF-κB unbalance and dysfunction in acute and age-related neurodegenerative disease. EJND (2014). (in press).
65. Hong EJ, McCord AE, Greenberg ME. A biological function for the neuronal activity-dependent component of Bdnf transcription in the development of cortical inhibition. Neuron (2008) 60(4):610-24. doi:10.1016/j.neuron.2008.09.024.
66. Tao J, Ji F, Liu B, Wang F, Dong F, Zhu Y. Improvement of deficits by transplantation of lentiviral vector-modified human amniotic mesenchymal cells after cerebral ischemia in rats. Brain Res (2012) 1448:1-10. doi:10.1016/j.brainres.2012.01.069.
67. Timmusk T, Palm K, Metsis M, Reintam T, Paalme V, Saarma M, et al. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron (1993) 10(3):475-89. doi:10.1016/0896-6273(93)90335-O.
68. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry (2006) 11(12):1116-25. doi:10.1038/sj.mp.4001893.
69. Chiu CT, Liu G, Leeds P, Chuang DM. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 36(12):2406-21. doi:10.1038/npp.2011.128.
70. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry (2009) 14(1):51-9. doi:10.1038/sj.mp.4002099.
71. Pranski E, Van Sanford CD, Dalal N, Orr AL, Karmali D, Cooper DS, et al. NF-κB activity is inversely correlated to RNF11 expression in Parkinson's disease. Neurosci Lett (2013) 547:16-20. doi:10.1016/j.neulet.2013.04.056.
72. Teismann P, Schwaninger M, Weih F, Ferger B. Nuclear factor-kappaB activation is not involved in a MPTP model of Parkinson's disease. Neuroreport (2001) 12(5):1049-53. doi:10.1097/00001756-200104170-00037.
73. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A (1998) 95(11):6469-73. doi:10.1073/pnas.95.11.6469.
74. Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 3(4):493-514. doi:10.3233/JPD-130250.
75. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci U S A (2008) 105(47):18578-83. doi:10.1073/pnas.0804373105.
76. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 8(4):382-97. doi:10.1016/S1474-4422(09)70062-6.
77. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem (2005) 280(48):40364-74. doi:10.1074/jbc.M509329200.
78. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience (2011) 198:221-31. doi:10.1016/j.neuroscience.2011.08.045.
79. Arbuthnott GW, Wickens J. Space, time and dopamine. Trends Neurosci (2007) 30(2):62-9. doi:10.1016/j.tins.2006.12.003.
80. Wilson CJ, Callaway JC. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol (2000) 83(5):3084-100.
81. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem (2006) 97(6):1634-58. doi:10.1111/j.1471-4159.2006.03907.x.
82. Cardozo-Pelaez F, Song S, Parthasarathy A, Hazzi C, Naidu K, Sanchez-Ramos J. Oxidative DNA damage in the aging mouse brain. Mov Disord (1999) 14(6):972-80. doi:10.1002/1531-8257(199911)14:6<972::AID-MDS1010>3.0.CO;2-0.
83. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem (2007) 103(1):17-37. doi:10.1111/j.1471-4159.2007.04764.x.
84. Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J (2005) 19(6):533-42. doi:10.1096/fj.04-2751com.
85. Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. Ann Neurol (2008) 64(Suppl 2):S65-80. doi:10.1002/ana.21472.
86. Kawahara TL, Michishita E, Adler AS, Damian M, Berber E, Lin M, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell (2009) 136(1):62-74. doi:10.1016/j.cell.2008.10.052.
87. Nasto LA, Seo HY, Robinson AR, Tilstra JS, Clauson CL, Sowa GA, et al. ISSLS prize winner: inhibition of NF-κB activity ameliorates age-associated disc degeneration in a mouse model of accelerated aging. Spine (Phila Pa 1976) (2012) 37(21):1819-25. doi:10.1097/BRS.0b013e31824ee8f7.